Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 8, 2013

View Archived Issues

Optimal dose of PM-00104 determined in phase II multiple myeloma study

OncoTherapy patents novel potential cancer vaccines

University of California discloses novel NGF muteins

The discovery of a cell signaling molecule that protects against diet-induced insulin resistance

Results reported from phase II study of chaperone-ERT in Pompe's disease

Novel molecular techniques to prevent immune rejection following pancreatic islet transplantation

New microfluidic platform developed for the highly sensitive detection of malaria

Clinical evaluation of the safety and tolerability of HIV vaccine alternative

SymBio receives trial notification acceptance for phase II Treakisym trial

Japan Tobacco files JTT-751 NDA in Japan

Pazopanib/paclitaxel combination found potentially beneficial for anaplastic thyroid cancer

European orphan drug designation recommended for VAL-083 for glioma

EnVivo Pharmaceuticals begins phase II trial of EVP-0962 in Alzheimer's disease

Labrys Biologics acquires antibody for chronic migraine from Pfizer

Scil Proteins presents new fusion proteins for cancer and infections

Edison Pharmaceuticals commences phase IIb trial in Friedreich's ataxia

Chinese scientists prepare novel protein kinase receptor antagonists

Agios Pharmaceuticals presents new IDH1 inhibitors

CrystalGenomics reports topline data from phase IIa CG-400549 study

CalciMedica presents new calcium channel blockers

EntreMed files trial application in China, opens second trial site in U.S., for ENMD-2076

BioMarin Pharmaceutical acquires Zacharon Pharmaceuticals

Oravig launched in U.S.

Durata Therapeutics' DISCOVER 1 trial meets primary endpoints

Boehringer Ingelheim and Eli Lilly report topline data for empagliflozin

First-in-human phase Ib study of ARGX-110 begins

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...